Complement component C1q and apoptotic index of B and T lymphocytes in patients with systemic lupus erythematosus;C1q složka komplementu a apoptotické indexy B a T lymfocytů ve skupině nemocných se systé movým lupus erythematodes

Ceska Revmatologie

Volumn 12, Issue 2, 2004, Pages 69-75

  Horak P ^a   Hermanova Z ^a   Ordeltova J ^a   Ciferska H ^b   Faltynek L ^a   Kusa L ^a   Zurek M ^a   Budikova M ^a   Vavrdova V ^a   Opichalova D ^a   Scudla V ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b FN a NP Olomouc ^*

Author keywords

Apoptosis; C1q; Complement; Lymphocytes; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DNA ANTIBODY; DOUBLE STRANDED DNA; METHOTREXATE;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; IMMUNODIFFUSION; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE SUBPOPULATION; MALE; PHAGOCYTOSIS; REGRESSION ANALYSIS; STAINING; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 3042625142     PISSN: 12107905     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology 1999; 42: 47-52.
2. Walport MJ, Davies KA, Botto M. C1q and systemic lupus erythematosus. Immunobiology 1998; 199: 265-285.
3. Mitchell DA, Pickering MC, Warren J et al. C1q deficiency and autoimmunity: the effects of genetic background on disease expression. J Immunol 2002; 168: 2538-2543.
4. Trendelenburg M, Schifferli JA. Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus. Zeitschrift fur Rheumatologie 2000; 59: 172-175.
5. Berkel AI, Petry F, Sanal O et al. Development of systemic lupus erythematosus in a patient with selective complement C1q deficiency. European Journal of Pediatrics 1997; 156: 113-115.
6. Dostál C, Vencovský J. Genetické podmínky systémového lupusu. In: Systémový lupus erytematodes. Medprint, 1997, 239.
7. Siegert CE, Daha MR. C1q as antigen in humoral autoimmune responses. Immunobiology 1998; 199: 295-302.
8. Monova D, Monov S, Rosenova K et al. Autoantibodies against C1q: view on association between systemic lupus erythematosus disease manifestation and C1q autoantibodies. Ann Rheum Dis 2002; 61: 563-564.
9. Horvath L, Czirjak L, Fekete B et al. High levels of antibodies against C1q are associated with disease activity and nephritis but not with other organ manifestations in SLE patients. Clin Exp Rheumatol 2001; 19: 667-672.
10. Bencivelli W, Vitali C, Isenberg DA et al. and the European Consensus Study Group for Disease Activity in SLE: Disease activity in systemic lupus erythematosus: Report of the consensus study group of the european workshop for rheumatology research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. Clin Exp Rheumatol 1992; 10: 549-554.
11. Bombardier C, Gladman DD, Urowitz MB et al. and The comittee on prognosis studies in SLE: Derivation of SLEDAI. Arthritis Rheum 1992; 35: 630-640.
12. Gladman DD, Urowitz MB. The SLICC/ACR damage index: progress report and experience in the field. Lupus 1999; 8: 632-637.
13. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classificatin of systemic lupus erythematosus. Arthritis Rheum 1982, 25: 1271-1277.
14. Stone NM, Williams A, Wilkinson JD et al. Systemic lupus erythematosus with C1q deficiency. Brit J Dermatol 2000; 142: 521-524.
15. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42: 833-843.
16. Bengtsson A, Nezlin R, Shoenfeld Y, Sturfelt G. DNA levels in circulating immune complexes decrease at severe SLE flares-correlation with complement component C1q. J Autoimm 1999; 13: 111-119.
17. Courtney PA, Crockard AD, Williamson K et al. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus 1999, 8: 508-513.
18. Walport MJ. Complement and systemic lupus erythematosus. Arthritis Research 2002; Suppl 3: S279-293.
19. Fremeaux-Bacchi V, Noel LH, Schifferli JA. No lupus nephritis in the absence of antiC1q autoantibodies? Nephrol Dial Transplant 2002; 17: 2041-2043.
20. Berner B, Scheel AK, Schettler V et al. Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 2001; 60: 898-899.
21. Pfueller B, Wolbart K, Bruns A et al. Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 2001; 44: 1962-1963.
22. Korb LC, Ahearn JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol 1997; 158: 4525-4528.
23. Botto M. Walport MJ. C1q, autoimmunity and apoptosis. Immunobiol 2002; 205: 395-406.
24. Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Advances in Immunology 2000; 76: 227-324.
25. Kumar A, Gupta R, Varghese T et al. Anti-C1q antibody as a marker of disease activity in systemic lupus erythematosus. Indian Journal of Medical Research 1999; 110: 190-193.
26. Horák P., Ščudla V., Heřmanová Z et al. Clinical Utility of Selected Disease Activity Markers in Patients with Systemic Lupus Erythematosus. Clin Rheumat 2001; 20: 337-344.